

PA 1256967

REC'D 13 JAN 2005

PCT

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

December 08, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.


APPLICATION NUMBER: 60/526,649

FILING DATE: December 03, 2003

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



P. R. Grant

P. R. GRANT
Certifying Officer

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53 (c).

19587 U.S. PTO
60/526649
120303

| | | | |
|--|--|---|--|
| DOCKET NUMBER | | T161SPVY | |
| INVENTOR(S) | | | |
| Given Name (first and middle (if any)) | Family Name or Surname | Residence (City and either State or Foreign Country) | |
| Dirk Michaela Ian Benito Petpiboon Abdul Nicholas S. | Beher Bettati Churcher Munoz Prasit Quddus Stock | Sawbridgeworth, Hertfordshire CM21 9PL, UK Sawbridgeworth, CM21 9PR, UK Dunmow, Essex, CM6 1XQ, UK San Diego, CA 92131, USA Rancho Santa Fe, CA 92067, USA Harlow, UK San Diego, CA 92109 | |
| <input checked="" type="checkbox"/> Additional inventors are being named on the 1 separately numbered sheets attached hereto | | | |
| TITLE OF THE INVENTION (500 characters max) | | | |
| THERAPEUTIC TREATMENT | | | |
| CORRESPONDENCE ADDRESS | | | |
| Direct all Correspondence to: Merck & Co., Inc. Patent Department - RY60-30 P.O. Box 2000 Rahway | | | |
| <input checked="" type="checkbox"/> Customer Number | | 000210 | |
| STATE | New Jersey | ZIP CODE | 07065 |
| COUNTRY | | U.S.A. | |
| ENCLOSED APPLICATION PARTS (check all that apply) | | | |
| <input checked="" type="checkbox"/> Specification | Number of Pages | 29 | <input type="checkbox"/> CD(s), Number |
| <input type="checkbox"/> Drawing(s) | Number of Sheets | | <input type="checkbox"/> Other (specify) |
| <input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 | | | |
| METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one) | | | |
| <input type="checkbox"/> A check or money order is enclosed to cover the filing fees | | FILING FEE AMOUNT (\$) | |
| <input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 13-2755 | | \$160.00 | |

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are: _____

Respectfully submitted,

SIGNATURE Raynard Yuro
TYPED or PRINTED NAME Raynard Yuro
TELEPHONE 732 594 0182

Date 12/03/2003

REGISTRATION NO. 45,570
(if appropriate)

OTE: Mail to Mail Stop Provisional Application

| | |
|---|--|
| EXPRESS MAIL CERTIFICATE | |
| DATE OF DEPOSIT | <u>December 3, 2003</u> |
| EXPRESS MAIL NO. | <u>EV321983648US</u> |
| I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450. | |
| MAILED BY | <u>Donna Schepise</u> DATE <u>December 3, 2003</u> |

PROVISIONAL APPLICATION COVER SHEET

Additional Page

| | | |
|--|------------------------|--|
| DOCKET NUMBER | | T1615PVY |
| INVENTOR(S)/APPLICANT(S) | | |
| Given Name (first and middle [if any]) | Family Name or Surname | Residence (City and either State or Foreign Country) |
| Jonathan D.J. | Wrigley | St. Albans, Herts, AL2 1JP, UK |

NUMBER 2 of 2

THERAPEUTIC TREATMENT

This invention relates to the use of methods and materials for use in therapeutic treatment of the human body. In particular, it provides methods of treating diseases associated with the deposition of β -amyloid peptide in the brain, such as Alzheimer's disease, or of preventing or delaying the onset of dementia associated with such diseases.

Alzheimer's disease (AD) is the most prevalent form of dementia. Its diagnosis is described in the Diagnostic and Statistical Manual of Mental Disorders, 4th ed., published by the American Psychiatric Association (DSM-IV). It is a neurodegenerative disorder, clinically characterized by progressive loss of memory and general cognitive function, and pathologically characterized by the deposition of extracellular proteinaceous plaques in the cortical and associative brain regions of sufferers. These plaques mainly comprise fibrillar aggregates of β -amyloid peptide ($A\beta$). $A\beta$ is formed from amyloid precursor protein (APP) via separate intracellular proteolytic events involving the enzymes β -secretase and γ -secretase. Variability in the site of the proteolysis mediated by γ -secretase results in $A\beta$ of varying chain length, e.g. $A\beta(1-38)$, $A\beta(1-40)$ and $A\beta(1-42)$. After secretion into the extracellular medium, the initially-soluble $A\beta$ forms aggregates which ultimately result in the insoluble deposits and dense neuritic plaques which are the pathological characteristics of AD.

Other dementing conditions associated with deposition of $A\beta$ in the brain include cerebral amyloid angiopathy, hereditary cerebral haemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.

Various interventions in the plaque-forming process have been proposed as therapeutic treatments for AD (see, for example, Hardy and Selkoe, *Science*, 297 (2002), 353-6). One such method of treatment that has been proposed is that of blocking or attenuating the production of $A\beta$, for example by inhibition of β - or γ -secretase. It has also been reported that inhibition of glycogen synthase kinase-3

(GSK-3), in particular inhibition of GSK-3 α , can block the production of A β (see Phiel et al, *Nature*, **423** (2003), 435-9).

Other proposed methods of treatment include administering a compound which blocks the aggregation of A β , and administering an antibody which selectively binds
5 to A β .


An alternative intervention in the plaque-forming process is that of modulation of the action of γ -secretase so as to selectively attenuate the production of A β (1-42). This results in preferential secretion of the shorter chain isoforms of A β , which are believed to have a reduced propensity for self-aggregation and plaque formation, and
10 hence are more easily cleared from the brain, and/or are less neurotoxic. Compounds showing this effect include certain non-steroidal antiinflammatory drugs (NSAIDs) and their analogues (see WO 01/78721 and US 2002/0128319 and Weggen et al *Nature*, **414** (2001) 212-16; Morihara et al, *J. Neurochem.*, **83** (2002), 1009-12; and Takahashi et al, *J. Biol. Chem.*, **278** (2003), 18644-70). Certain compounds which
15 modulate the activity of PPAR α and/or PPAR δ are also reported to have the effect of lowering A β (1-42) (WO 02/100836). NSAID derivatives capable of releasing nitric oxide have been reported to show improved anti-neuroinflammatory effects and/or to reduce intracerebral A β deposition in animal models (WO 02/092072; Jantzen et al, *J. Neuroscience*, **22** (2002), 226-54).

Recent results suggest that A β (1-42) can form soluble oligomers which exert a neurotoxic effect independent of plaque formation (Gong *et al*, *PNAS*, **100** (2003), 10417-22)
20

US 5,081,138 discloses a broad class of 1-benzyl-3-thio-substituted indole-2-alkanoic acids as inhibitors of leukotriene biosynthesis, useful in treatment of asthma,
25 allergies, inflammation, diarrhoea, hypertension, angina, platelet aggregation, cerebral spasm, premature labour, spontaneous abortion, dysmenorrhea and migraine. There is no disclosure or suggestion of any effect on the secretion of A β , or of any utility in the treatment or prevention of AD or any other disorders associated with deposition of A β in the brain.

It has now been found that certain 1-alkyl-3-thio-substituted indole-2-alkanoic acids have the desirable property of selectively inhibiting production of A β (1-42).
30

According to the present invention there is provided a method of treating or preventing a disease associated with deposition of A β in the brain comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I



(I)

5

wherein each R¹ is independently H, C₁₋₆alkyl or C₃₋₆cycloalkyl;

each R² is independently H or C₁₋₆alkyl, or the two R² groups together complete a C₃₋₆cycloalkyl group;

R³ represents a hydrocarbon group of up to 10 carbon atoms optionally bearing up to 2 substituents selected from halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl and C₁₋₄alkylcarbonyloxy; or R³ represents a heteroaryl group of 5 or 6 ring atoms which is optionally benzo-fused, optionally bearing up to 2 substituents selected from C₁₋₄alkyl, halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl and C₁₋₄alkylcarbonyloxy;

15

R⁴, R⁵ and R⁶ independently represent H, halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyloxy or hydrocarbon of up to 7 carbon atoms optionally bearing a substituent selected from halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl and C₁₋₄alkylcarbonyloxy;

20

R⁷ represents a hydrocarbon group of up to 10 carbon atoms optionally bearing up to 2 substituents selected from halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl and C₁₋₄alkylcarbonyloxy;

X represents O or S;

25

Y represents a bond, CH₂, CH₂CH₂, CH₂CH₂CH₂ or CH₂CH₂O; and

Z represents CO₂H or tetrazol-5-yl;

or a pharmaceutically acceptable salt thereof.

The disease associated with deposition of A β in the brain is typically Alzheimer's disease (AD), cerebral amyloid angiopathy, HCHWA-D, multi-infarct dementia, dementia pugilistica or Down syndrome, in particular AD.

5 In a second aspect, the invention provides a method of treating, preventing or delaying the onset of dementia associated with Alzheimer's disease, cerebral amyloid angiopathy, HCHWA-D, multi-infarct dementia, dementia pugilistica or Down syndrome comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I as defined above or a pharmaceutically
10 acceptable salt thereof.

The invention also provides the use, for the manufacture of a medicament for treatment or prevention of a disease associated with the deposition of β -amyloid in the brain, of a compound of formula I as defined above.

15 In a further aspect, the invention provides the use of a compound of Formula I as defined above, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating, preventing or delaying the onset of dementia associated with Alzheimer's disease, cerebral amyloid angiopathy, HCHWA-D, multi-infarct dementia, dementia pugilistica or Down syndrome.

20 The compounds of Formula I modulate the action of γ -secretase so as to selectively attenuate production of the (1-42) isoform of A β without significantly lowering production of the shorter chain isoforms such as A β (1-40). This results in secretion of A β which has less tendency to self-aggregate and form insoluble deposits, is more easily cleared from the brain, and/or is less neurotoxic. Therefore, a further
25 aspect of the invention provides a method for retarding, arresting or preventing the accumulation of A β in the brain comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I as defined above or a pharmaceutically acceptable salt thereof.

30 Because the compounds of formula I modulate the activity of γ -secretase, as opposed to suppressing said activity, it is believed that the therapeutic benefits described above will be obtained with a reduced risk of side effects, e.g. those that

might arise from a disruption of the Notch signalling process which is controlled by γ -secretase.

In one embodiment of the invention, the compound of Formula I is administered to a patient suffering from AD, cerebral amyloid angiopathy, HCHWA-D, multi-infarct dementia, dementia pugilistica or Down syndrome, in particular a patient suffering from AD.

In an alternative embodiment of the invention, the compound of Formula I is administered to a patient suffering from mild cognitive impairment or age-related cognitive decline. A favourable outcome of such treatment is prevention or delay of the onset of AD. Age-related cognitive decline and mild cognitive impairment (MCI) are conditions in which a memory deficit is present, but other diagnostic criteria for dementia are absent (Santacruz and Swagerty, *American Family Physician*, **63** (2001), 703-13). (See also "The ICD-10 Classification of Mental and Behavioural Disorders", Geneva: World Health Organisation, 1992, 64-5). As used herein, "age-related cognitive decline" implies a decline of at least six months' duration in at least one of: memory and learning; attention and concentration; thinking; language; and visuospatial functioning and a score of more than one standard deviation below the norm on standardized neuropsychologic testing such as the MMSE. In particular, there may be a progressive decline in memory. In the more severe condition MCI, the degree of memory impairment is outside the range considered normal for the age of the patient but AD is not present. The differential diagnosis of MCI and mild AD is described by Petersen *et al.*, *Arch. Neurol.*, **56** (1999), 303-8.

Within this embodiment, the compound of Formula I is advantageously administered to patients who suffer impaired memory function but do not exhibit symptoms of dementia. Such impairment of memory function typically is not attributable to systemic or cerebral disease, such as stroke or metabolic disorders caused by pituitary dysfunction. Such patients may be in particular people aged 55 or over, especially people aged 60 or over, and preferably people aged 65 or over. Such patients may have normal patterns and levels of growth hormone secretion for their age. However, such patients may possess one or more additional risk factors for developing Alzheimer's disease. Such factors include a family history of the disease; a

genetic predisposition to the disease; elevated serum cholesterol; and adult-onset diabetes mellitus.

In a particular embodiment of the invention, the compound of Formula I is administered to a patient suffering from age-related cognitive decline or MCI who additionally possesses one or more risk factors for developing AD selected from: a family history of the disease; a genetic predisposition to the disease; elevated serum cholesterol; and adult-onset diabetes mellitus.

A genetic predisposition (especially towards early onset AD) can arise from point mutations in one or more of a number of genes, including the APP, presenilin-1 and presenilin-2 genes. Also, subjects who are homozygous for the $\epsilon 4$ isoform of the apolipoprotein E gene are at greater risk of developing AD.

The patient's degree of cognitive decline or impairment is advantageously assessed at regular intervals before, during and/or after a course of treatment in accordance with the invention, so that changes therein may be detected, e.g. the slowing or halting of cognitive decline. A variety of neuropsychological tests are known in the art for this purpose, such as the Mini-Mental State Examination (MMSE) with norms adjusted for age and education (Folstein *et al.*, *J. Psych. Res.*, **12** (1975), 196-198, Anthony *et al.*, *Psychological Med.*, **12** (1982), 397-408; Cockrell *et al.*, *Psychopharmacology*, **24** (1988), 689-692; Crum *et al.*, *J. Am. Med. Assoc'n.* **18** (1993), 2386-2391). The MMSE is a brief, quantitative measure of cognitive status in adults. It can be used to screen for cognitive decline or impairment, to estimate the severity of cognitive decline or impairment at a given point in time, to follow the course of cognitive changes in an individual over time, and to document an individual's response to treatment. Another suitable test is the Alzheimer Disease Assessment Scale (ADAS), in particular the cognitive element thereof (ADAS-cog) (See Rosen *et al.*, *Am. J. Psychiatry*, **141** (1984), 1356-64).

Where a variable occurs more than once in formula I or in a substituent thereof, the individual occurrences of that variable are independent of each other, unless otherwise specified.

As used herein, the expression "hydrocarbon group" refers to groups consisting solely of carbon and hydrogen atoms. Such groups may comprise linear, branched or cyclic structures, singly or in any combination consistent with the indicated maximum

number of carbon atoms, and may be saturated or unsaturated, including aromatic when the indicated maximum number of carbon atoms so permits unless otherwise indicated.

As used herein, the expression "C_{1-x}alkyl" where x is an integer greater than 1
5 refers to straight-chained and branched alkyl groups wherein the number of constituent carbon atoms is in the range 1 to x. Particular alkyl groups are methyl, ethyl, n-propyl, isopropyl and t-butyl. Derived expressions such as "C₂₋₆alkenyl", "hydroxyC₁₋₆alkyl", "heteroarylC₁₋₆alkyl", "C₂₋₆alkynyl" and "C₁₋₆alkoxy" are to be construed in an analogous manner. Most suitably, the number of carbon atoms in such groups is not
10 more than 6.

The term "halogen" as used herein includes fluorine, chlorine, bromine and iodine, of which fluorine and chlorine are preferred.

The term "heteroaryl" as used herein refers to an aromatic ring in which one or more of the ring atoms is other than carbon. Preferably, said one or more ring atoms
15 are selected from N, O and S.

For use in medicine, the compounds of formula I may be in the form of pharmaceutically acceptable salts. Other salts may, however, be useful in the preparation of the compounds of formula I or of their pharmaceutically acceptable salts. Suitable pharmaceutically acceptable salts of the compounds of this invention
20 include acid addition salts which may, for example, be formed by mixing a solution of the compound according to the invention with a solution of a pharmaceutically acceptable acid such as hydrochloric acid, sulphuric acid, methanesulphonic acid, benzenesulphonic acid, fumaric acid, maleic acid, succinic acid, acetic acid, benzoic acid, oxalic acid, citric acid, tartaric acid, carbonic acid or phosphoric acid.

Alternatively, where the compound of the invention carries an acidic moiety, a pharmaceutically acceptable salt may be formed by neutralisation of said acidic moiety with a suitable base. Examples of pharmaceutically acceptable salts thus formed
25 include alkali metal salts such as sodium or potassium salts; ammonium salts; alkaline earth metal salts such as calcium or magnesium salts; and salts formed with suitable
30 organic bases, such as amine salts (including pyridinium salts) and quaternary ammonium salts.

Where the compounds according to the invention have at least one asymmetric centre, they may accordingly exist as enantiomers. Where the compounds according to the invention possess two or more asymmetric centres, they may additionally exist as diastereoisomers. It is to be understood that all such isomers and mixtures thereof
5 in any proportion are encompassed within the scope of the present invention.

In formula I, X represents O or S. In a preferred embodiment, X represents S.

Y represents a bond, CH₂, CH₂CH₂, CH₂CH₂CH₂ or CH₂CH₂O. Typically, Y represents a bond, CH₂ or CH₂CH₂O, and preferably represents CH₂.

Z represents CO₂H or tetrazol-5-yl. Preferably, Z represents CO₂H.

10 In Formula I, each R¹ is independently H, C₁₋₆ alkyl or C₃₋₆ cycloalkyl. Examples include H, methyl, ethyl, propyl and cyclopropyl. Preferably at least one R¹ is H. In one preferred embodiment, both R¹ groups are H. In another preferred embodiment, one R¹ is H and the other is methyl, ethyl or propyl, preferably methyl.

Each R² is independently H or C₁₋₆alkyl (such as methyl or ethyl), or the two
15 R² groups together complete a cycloalkane of 3-6 members (such as cyclopentane or cyclohexane). Preferably, at least one R² is other than H, and most preferably neither R² is H. In a preferred embodiment both R² groups are methyl.

R³ represents hydrocarbon of up to 10 carbon atoms, optionally substituted as defined previously, or heteroaryl of 5 to 6 atoms, optionally benzo-fused, optionally
20 substituted as defined previously. Typical hydrocarbon groups include alkyl (especially branched alkyl, such as t-butyl), cycloalkyl (such as cyclohexyl), phenyl, phenyl-substituted alkyl (such as benzyl), and alkyl-substituted phenyl (such as toluyl or xylyl). Preferred substituents (where present) include halogen, especially Cl. Typical heteroaryl rings include pyridine, quinoline, isoquinoline, thiazole and
25 benzothiazole, on which the preferred substituents (where present) include halogen, especially Cl.

In a preferred embodiment, R³ is selected from alkyl, cycloalkyl, alkyl-substituted phenyl and chloro-substituted phenyl.

Specific examples of groups represented by R³ include t-butyl, cyclohexyl,
30 phenyl, 2,5-dimethylphenyl, 2,6-dimethylphenyl, 3,5-dimethylphenyl, 3,4-dimethylphenyl, 2,4-dimethylphenyl, 4-chlorophenyl, 3,4-dichlorophenyl and 5-chlorobenzothiazol-2-yl.

R^4 , R^5 and R^6 are perfectly selected from H, halogen, CN, CF_3 , OCF_3 , C_{1-6} alkoxy, C_{1-6} alkyl and optionally-substituted phenyl. Preferably, at least one of R^4 , R^5 and R^6 is other than H. When two or more of R^4 , R^5 and R^6 are other than H, they are very aptly selected from C_{1-6} alkyl and halogen. R^4 , R^5 and R^6 may occupy any of the available ring positions, but in one preferred embodiment, two of R^4 , R^5 and R^6 are H and the third is attached to the 5-position. Specific examples of groups represented by R^4 , R^5 and R^6 include H, methyl, isopropyl, Cl, Br, F, CF_3 , OCF_3 and phenyl.

Examples of hydrocarbon groups represented by R^7 include alkyl (e.g. of up to 6 carbon atoms, such as methyl, ethyl, propyl or butyl), which is optionally substituted as defined previously; alkenyl (e.g. of up to 6 carbon atoms, such as vinyl or allyl), cycloalkyl (e.g. of up to 6 carbon atoms, such as cyclohexyl), and optionally substituted phenyl. Phenyl groups represented by R^7 preferably bear at least one substituent, and preferably not more than two substituents. If more than two substituents are present, at least one of them must be C_{1-4} alkyl. When a single substituent is present, it is preferably (but not necessarily) in the 4-position. Examples of preferred substituents include C_{1-4} alkyl (such as methyl, ethyl, propyl and butyl, especially t-butyl); halogen (especially Cl and F); CN; CF_3 ; OCF_3 ; CO_2H and C_{1-4} alkylthio (especially methylthio). Specific examples of groups represented by R^7 include methyl, methoxymethyl, vinyl, cyclohexyl, phenyl, 4-chlorophenyl, 4-trifluoromethylphenyl, 4-fluorophenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 4-trifluoromethoxyphenyl, 4-t-butylphenyl, 3,5-bis(trifluoromethyl)phenyl, 4-methylthiophenyl, 4-cyanophenyl, 3-trifluoromethylphenyl and 3-carboxyphenyl.

Specific examples suitable for use in the invention include the compounds of formula I in which X is S, Y is CH_2 , Z is CO_2H , one R^1 group is H, both R^2 groups are Me (unless otherwise indicated), and the remaining variables are as shown in the following table:

Table 1

| R^1 | R^3 | R^4, R^5, R^6 | R^7 |
|-------|--------------|-----------------|---------------|
| Me | 2,5-di-Me-Ph | 5-isopropyl | 4-Cl-Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | 4- CF_3 -Ph |

| R ¹ | R ³ | R ⁴ ,R ⁵ ,R ⁶ | R ⁷ |
|----------------|----------------|--|----------------------------|
| Me | 2,5-di-Me-Ph | 5-isopropyl | Me |
| H | 2,6-di-Me-Ph | 5-isopropyl | 4-CF ₃ -Ph |
| H | 3,5-di-Me-Ph | 5-isopropyl | 4-CF ₃ -Ph |
| Me | 2,5-di-Me-Ph | 5-isopropyl | 4-CF ₃ -Ph |
| H | 2,5-di-Me-Ph | 5-F | 4-CF ₃ -Ph |
| H | 3,4-di-Me-Ph | 5-isopropyl | 2,4-di-F-Ph |
| H | 2,5-di-Me-Ph | 5-Br | 4-CF ₃ -Ph |
| H | 2,5-di-Me-Ph | 5-Br | 4-Cl-Ph |
| H | 2,5-di-Me-Ph | 5-Cl | 4-CF ₃ -Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | 2,4-di-Cl-Ph |
| H | 2,5-di-Me-Ph | 5-OCF ₃ | 4-CF ₃ -Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | 2,4-di-CF ₃ -Ph |
| H | 3,5-di-Me-Ph | 5-isopropyl | 4-Cl-Ph |
| Et | 2,5-di-Me-Ph | 5-isopropyl | 4-CF ₃ -Ph |
| H | 2,5-di-Me-Ph | 5-Cl | 4-Cl-Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | cyclohexyl |
| H | 2,5-di-Me-Ph | 5-isopropyl | 4-CF ₃ O-Ph |
| H | 3,4-di-Me-Ph | 5-isopropyl | 4-CF ₃ -Ph |
| H | 2,5-di-Me-Ph | 5-CF ₃ | 4-CF ₃ -Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | 2,4-di-F-Ph |
| H | 2,5-di-Me-Ph | 5-CF ₃ O | 2,4-di-F-Ph |
| H | 2,4-di-Me-Ph | 5-isopropyl | 4-CF ₃ -Ph |
| H | 2,6-di-Me-Ph | 5-isopropyl | 4-Cl-Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | Ph |
| H | 2,5-di-Me-Ph | 5-t-butyl | 4-CF ₃ -Ph |
| H | 2,5-di-Me-Ph | 5-F | 4-Cl-Ph |
| cyclopropyl | 2,5-di-Me-Ph | 5-isopropyl | 4-CF ₃ -Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | 4-t-butyl-Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | 3,5-di-CF ₃ -Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | 4-Cl-Ph |

| R ¹ | R ³ | R ⁴ ,R ⁵ ,R ⁶ | R ⁷ |
|----------------|------------------------|--|-----------------------|
| H | 2,5-di-Me-Ph | 6,7-di-Me | 4-CF ₃ -Ph |
| H | 2,4-di-Me-Ph | 5-isopropyl | 4-Cl-Ph |
| H | cyclohexyl | 5-isopropyl | 4-Cl-Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | 4-MeS-Ph |
| H | 2,5-di-Me-Ph | 6,7-di-Me | 4-Cl-Ph |
| H | 2,5-di-Cl-Ph | 5-isopropyl | 2,4-di-F-Ph |
| H | 2,5-di-Cl-Ph | 5-isopropyl | 4-CF ₃ -Ph |
| H | 2,5-di-Me-Ph | 5,7-di-Me | 4-Cl-Ph |
| H | 2,5-di-Me-Ph | 5-CF ₃ O | 4-F-Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | vinyl |
| H | 2,5-di-Me-Ph | 5-Cl | 4-CN-Ph |
| H | 2,5-di-Me-Ph | 5-CF ₃ O | 3-Cl-Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | MeOCH ₂ |
| H | 2,5-di-Me-Ph | 5-CF ₃ O | 4-Cl-Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | 3-CF ₃ -Ph |
| H | 2,5-di-Me-Ph | 5-F | 4-CN-Ph |
| H | 3,4-di-Cl-Ph | 5-isopropyl | 4-CF ₃ -Ph |
| H* | t-butyl | 5-isopropyl | 4-Cl-Ph |
| H | 4-Cl-Ph | 5-isopropyl | 4-Cl-Ph |
| H | 3,4-di-Me-Ph | 5-isopropyl | 4-Cl-Ph |
| H | 3,4-di-Cl-Ph | 5-isopropyl | 4-Cl-Ph |
| H | t-butyl | 5-Ph | 4-Cl-Ph |
| H | 2,5-di-Me-Ph | 5-isopropyl | 3-HOOC-Ph |
| H | t-butyl | 5-isopropyl | 4-Cl-Ph |
| H | 5-Cl-benzothiazol-2-yl | 5-isopropyl | 4-Cl-Ph |


* the two R² groups together complete a cyclopentyl ring.

Further specific compounds suitable for use in the invention include compounds of formula I in which each R¹ is H, R⁴ is 5-isopropyl, R⁵ and R⁶ are H, R⁷

5 is 4-chlorophenyl and the remaining variables are as shown in table 2:

| R^2/R^2 | R^3 | X | Y | Z |
|----------------|-----------|---|-------------|---------------|
| H, H | t-butyl | S | bond | tetrazol-5-yl |
| H, H | t-butyl | S | CH_2CH_2O | CO_2H |
| H, methyl | t-butyl | S | CH_2CH_2O | CO_2H |
| methyl, methyl | sec-butyl | O | CH_2 | CO_2H |


A first subset of the compounds of Formula I is defined by Formula II:



- 5 wherein R^{1a} represents C_{1-6} alkyl or C_{3-6} cycloalkyl, and R^2 - R^7 , X, Y and Z have the same definitions and preferred identities as before.

Compounds of Formula II and the pharmaceutically acceptable salts thereof are believed to be novel and hence constitute a further aspect of the invention. Preferably, X is S, Y is CH_2 and Z is CO_2H .

- 10 A second subset of the compounds of Formula I is defined by Formula III:



wherein n is 1 or 2 and R¹-R⁶, X, Y and Z have the same definitions and preferred identities as before.

Compounds of formula III and the pharmaceutically acceptable salts thereof are believed to be novel, and hence constitute a further aspect of the invention. In a preferred embodiment, n is 1 and the CF₃ group is in the 4-position. Typically, X is S,
5 Y is CH₂ and Z is CO₂H.

The invention also provides a pharmaceutical composition comprising, in a pharmaceutically acceptable carrier, a compound in accordance with Formula II or Formula III or a pharmaceutically acceptable salt thereof.

10 The synthesis of compounds of Formula I in which R⁷ is optionally-substituted phenyl is described in US 5,081,138, the entire disclosure of which is incorporated herein by reference. Analogous methods may be used to prepare the corresponding compounds in which R⁷ has its alternative identities.

Since the compounds of Formulae I, II and III may have one or more
15 asymmetric centres, they accordingly may exist in enantiomeric forms. If desired, the individual enantiomers may be isolated in pure form by conventional means. For example, a racemic mixture may be resolved into its component enantiomers by preparative chiral HPLC, or by treatment with an optically pure amine to form diastereomeric salt pairs, separable by fractional crystallisation, from which the
20 optically pure acids may be regenerated. Similarly, a racemic acid may be reacted with an optically pure alcohol or amine to form pairs of diastereomeric esters or amides which may be separated by chromatography or fractional crystallisation and hydrolysed to yield enantiomerically-pure acids. These resolution techniques may equally well be practised on the synthetic precursors of the compounds of Formulae I,
25 II and III and the resulting optically-pure intermediates used to prepare compounds of Formulae I, II and III in optically-pure form.

The compounds of Formulae I, II and III are typically used in the form of pharmaceutical compositions comprising one or more compounds of Formula I, II or III and a pharmaceutically acceptable carrier. Preferably these compositions are in
30 unit dosage forms such as tablets, pills, capsules, powders, granules, sterile parenteral solutions or suspensions, metered aerosol or liquid sprays, drops, ampoules, transdermal patches, auto-injector devices or suppositories; for oral, parenteral,

intranasal, sublingual or rectal administration, or for administration by inhalation or insufflation. The principal active ingredient typically is mixed with a pharmaceutical carrier, e.g. conventional tableting ingredients such as corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate and dicalcium phosphate, or gums, dispersing agents, suspending agents or surfactants such as sorbitan monooleate and polyethylene glycol, and other pharmaceutical diluents, e.g. water, to form a homogeneous preformulation composition containing a compound of the present invention, or a pharmaceutically acceptable salt thereof. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This preformulation composition is then subdivided into unit dosage forms of the type described above containing from 0.1 to about 500 mg of the active ingredient of the present invention. Typical unit dosage forms contain from 1 to 100 mg, for example 1, 2, 5, 10, 25, 50 or 100 mg, of the active ingredient. Tablets or pills of the composition can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permits the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.

25 The liquid forms in which the compositions useful in the present invention may be incorporated for administration orally or by injection include aqueous solutions, liquid- or gel-filled capsules, suitably flavoured syrups, aqueous or oil suspensions, and flavoured emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil or peanut oil, as well as elixirs and similar pharmaceutical vehicles.

30 Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium

carboxymethylcellulose, methylcellulose, poly(ethylene glycol), poly(vinylpyrrolidone) or gelatin.


For treating or preventing Alzheimer's disease, a suitable dosage level is about 0.01 to 250 mg/kg per day, preferably about 0.01 to 100 mg/kg per day, and more preferably about 0.05 to 50 mg/kg of body weight per day, of the active compound. The compounds may be administered on a regimen of 1 to 4 times per day. In some cases, however, a dosage outside these limits may be used.

The compounds of Formula I optionally may be administered in combination with one or more additional compounds known to be useful in the treatment or prevention of AD or the symptoms thereof. Such additional compounds thus include cognition-enhancing drugs such as acetylcholinesterase inhibitors (e.g. donepezil and galanthamine), NMDA antagonists (e.g. memantine) or PDE4 inhibitors (e.g. Ariflo™ and the classes of compounds disclosed in WO 03/018579, WO 01/46151, WO 02/074726 and WO 02/098878). Such additional compounds also include cholesterol-lowering drugs such as the statins, e.g. simvastatin. Such additional compounds similarly include compounds known to modify the production or processing of A β in the brain ("amyloid modifiers"), such as compounds which inhibit the secretion of A β (including γ -secretase inhibitors, β -secretase inhibitors, and GSK-3 α inhibitors), compounds which inhibit the aggregation of A β , and antibodies which selectively bind to A β .

In this embodiment of the invention, the amyloid modifier may be a compound which inhibits the secretion of A β , for example an inhibitor of γ -secretase (such as those disclosed in WO 01/53255, WO 01/66564, WO 01/70677, WO 01/90084, WO 01/77144, WO 02/30912, WO 02/36555, WO 02/081435, WO 02/081433, WO 03/018543, WO 03/013506, WO 03/013527 and WO 03/014075), or a β -secretase inhibitor (such as those disclosed in WO 03/037325, WO 03/030886, WO 03/006013, WO 03/006021, WO 03/006423, WO 03/006453, WO 02/002122, WO 01/70672, WO 02/02505, WO 02/02506, WO 02/02512, WO 02/02520, WO 02/098849 and WO 02/100820), or any other compound which inhibits the formation or release of A β , including those disclosed in WO 98/28268, WO 02/47671, WO 99/67221, WO 01/34639, WO 01/34571, WO 00/07995, WO

00/38618, WO 01/92235, WO 01/77086, WO 01/74784, WO 01/74796, WO 01/74783, WO 01/60826, WO 01/19797, WO 01/27108, WO 01/27091, WO 00/50391, WO 02/057252, US 2002/0025955 and US2002/0022621, and also including GSK-3 inhibitors, particularly GSK-3 α inhibitors, such as lithium, as disclosed in Phiel et al, *Nature*, 423 (2003), 435-9.

Within this embodiment, the amyloid modifier is advantageously a γ -secretase inhibitor, preferred examples of which include a compound of formula XI:



wherein:

m is 0 or 1;

Z represents halogen, CN, NO₂, N₃, CF₃, OR^{2a}, N(R^{2a})₂, CO₂R^{2a}, OCOR^{2a}, COR^{2a}, CON(R^{2a})₂, OCON(R^{2a})₂, CONR^{2a}(OR^{2a}), CON(R^{2a})N(R^{2a})₂, CONHC(=NOH)R^{2a}, heterocyclyl, phenyl or heteroaryl, said heterocyclyl, phenyl or heteroaryl bearing 0-3 substituents selected from halogen, CN, NO₂, CF₃, OR^{2a},

N(R^{2a})₂, CO₂R^{2a}, COR^{2a}, CON(R^{2a})₂ and C₁₋₄alkyl;

R^{1b} represents H, C₁₋₄alkyl or OH;

R^{1c} represents H or C₁₋₄alkyl;

with the proviso that when m is 1, R^{1b} and R^{1c} do not both represent C₁₋₄alkyl;

Ar¹ represents C₆₋₁₀aryl or heteroaryl, either of which bears 0-3 substituents

independently selected from halogen, CN, NO₂, CF₃, OH, OCF₃, C₁₋₄alkoxy or C₁₋₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁₋₄alkoxy;

Ar² represents C₆₋₁₀aryl or heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CN, NO₂, CF₃, OH, OCF₃, C₁₋₄alkoxy or

C₁₋₄alkyl which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH and C₁₋₄alkoxy;

R^{2a} represents H, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₆alkyl, C₂₋₆alkenyl, any of which optionally bears a substituent selected from halogen, CN, NO₂,

CF₃, OR^{2b}, CO₂R^{2b}, N(R^{2b})₂, CON(R^{2b})₂, Ar and COAr; or R^{2a} represents Ar; or two R^{2a} groups together with a nitrogen atom to which they are mutually attached may complete an N-heterocyclyl group bearing 0-4 substituents independently selected from =O, =S, halogen, C₁₋₄alkyl, CN, NO₂, CF₃, OH, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, CO₂H, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, carbamoyl, Ar and COAr;

R^{2b} represents H, C₁₋₆alkyl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylC₁₋₆alkyl, C₂₋₆alkenyl, any of which optionally bears a substituent selected from halogen, CN, NO₂, CF₃, OH, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, CO₂H, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, carbamoyl, Ar and COAr; or R^{2b} represents Ar; or two R^{2b} groups together with a nitrogen atom to which they are mutually attached may complete an N-heterocyclyl group bearing 0-4 substituents independently selected from =O, =S, halogen, C₁₋₄alkyl, CN, NO₂, CF₃, OH, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, CO₂H, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, carbamoyl, Ar and COAr;


Ar represents phenyl or heteroaryl bearing 0-3 substituents selected from halogen, C₁₋₄alkyl, CN, NO₂, CF₃, OH, C₁₋₄alkoxy, C₁₋₄alkoxycarbonyl, amino, C₁₋₄alkylamino, di(C₁₋₄alkyl)amino, carbamoyl, C₁₋₄alkylcarbamoyl and di(C₁₋₄alkyl)carbamoyl;

"heterocyclyl" at every occurrence thereof means a cyclic or polycyclic system of up to 10 ring atoms selected from C, N, O and S, wherein none of the constituent rings is aromatic and wherein at least one ring atom is other than C; and

"heteroaryl" at every occurrence thereof means a cyclic or polycyclic system of up to 10 ring atoms selected from C, N, O and S, wherein at least one of the constituent rings is aromatic and wherein at least one ring atom of said aromatic ring is other than C;


or a pharmaceutically acceptable salt thereof.

Such compounds may be prepared as described in WO 03/018543. Preferred examples include those defined by formula XIa:



and the pharmaceutically acceptable salts thereof, wherein m is 0 or 1, X is Cl or CF₃, and Y is OH, OC₁₋₆alkyl, NH₂ or NHC₁₋₆alkyl. Particular examples include those in which m is 1 and Y is OH (or the sodium salts thereof), and those in which m is 0 and Y is NH₂ or NHC₁₋₆alkyl.

Another preferred class of γ -secretase inhibitors for use in this embodiment of the invention is that defined by formula XII:



wherein X is a bivalent pyrazole, imidazole, triazole, oxazole, isoxazole, thiazole, isothiazole, thiadiazole or 1,3,4-oxadiazole residue optionally bearing a hydrocarbon substituent comprising 1-5 carbon atoms which is optionally substituted with up to 3 halogen atoms; and

R is selected from:

- (i) CF₃ or a non-aromatic hydrocarbon group of up to 10 carbon atoms, optionally substituted with halogen, CF₃, CHF₂, CN, OH, CO₂H, C₂₋₆acyl, C₁₋₄alkoxy or C₁₋₄alkoxycarbonyl;
- (ii) a non-aromatic heterocyclic group comprising up to 7 ring atoms of which up to 3 are chosen from N, O and S and the remainder are carbon, bearing 0-3 substituents independently selected from oxo, halogen, CN, C₁₋₆alkyl, OH, CF₃, CHF₂, CH₂F, C₂₋₆acyl, CO₂H, C₁₋₄alkoxy and C₁₋₄alkoxycarbonyl;
- (iii) phenyl or 6-membered heteroaryl, either of which bears 0-3 substituents independently selected from halogen, CF₃, CHF₂, CH₂F, NO₂, CN, OCF₃, C₁₋₆alkyl and C₁₋₆alkoxy; and

(iv) $N(R^a)_2$ where each R^a independently represents H or C_{1-6} alkyl which is optionally substituted with halogen, CF_3 , CHF_2 , CN, OH, CO_2H , C_{2-6} acyl, C_{1-4} alkoxy or C_{1-4} alkoxycarbonyl; or a pharmaceutically acceptable salt thereof.

5 X is very aptly 5-substituted-thiazol-2-yl, 5-substituted-4-methylthiazol-2-yl, 5-substituted-1-methylpyrazol-3-yl, 1-substituted-imidazol-4-yl or 1-substituted-1,2,4-triazol-3-yl. Preferably, R represents optionally-substituted phenyl or heteroaryl such as phenyl, monohalophenyl, dihalophenyl, trihalophenyl, cyanophenyl, methylphenyl, methoxyphenyl, trifluoromethylphenyl, trifluoromethoxyphenyl, pyridyl,
10 monohalopyridyl and trifluoromethylpyridyl, wherein "halo" refers to fluoro or chloro. Particularly preferred identities of R-X- include 5-(4-fluorophenyl)-1-methylpyrazol-3-yl, 5-(4-chlorophenyl)-1-methylpyrazol-3-yl and 1-(4-fluorophenyl)imidazol-4-yl. Such compounds may be prepared by methods similar to those disclosed in WO 02/36555.

15 Alternatively, the amyloid modifier may be a compound which inhibits the aggregation of A β . Suitable examples include chelating agents such as clioquinol (Gouras and Beal, *Neuron*, 30 (2001), 641-2) and the compounds disclosed in WO 99/16741, in particular that known as DP-109 (Kalendarev et al, *J. Pharm. Biomed. Anal.*, 24 (2001), 967-75). Other inhibitors of A β aggregation suitable for use in the
20 invention include the compounds disclosed in WO 96/28471, WO 98/08868 and WO 00/052048, including the compound known as ApanTM (Praecis); WO 00/064420, WO 03/017994, WO 99/59571 and the compound known as AlzhemedTM (Neurochem); WO 00/149281 and the compositions known as PTI-777 and PTI-00703 (ProteoTech); WO 96/39834, WO 01/83425, WO 01/55093, WO 00/76988, WO 00/76987, WO
25 00/76969, WO 00/76489, WO 97/26919, WO 97/16194, and WO 97/16191.

Alternatively, the amyloid modifier may be an antibody which binds selectively to A β . Said antibody may be polyclonal or monoclonal, but is preferably monoclonal, and is preferably human or humanized. Preferably, the antibody is capable of sequestering soluble A β from biological fluids, as described in WO
30 03/016466, WO 03/016467, WO 03/015691 and WO 01/62801. Suitable antibodies include humanized antibody 266 (described in WO 01/62801) and the modified version thereof described in WO 03/016466.

As used herein, the expression "in combination with" requires that therapeutically effective amounts of both the compound of Formula I and the additional compound are administered to the subject, but places no restriction on the manner in which this is achieved. Thus, the two species may be combined in a single dosage form for simultaneous administration to the subject, or may be provided in separate dosage forms for simultaneous or sequential administration to the subject. Sequential administration may be close in time or remote in time, e.g. one species administered in the morning and the other in the evening. The separate species may be administered at the same frequency or at different frequencies, e.g. one species once a day and the other two or more times a day. The separate species may be administered by the same route or by different routes, e.g. one species orally and the other parenterally, although oral administration of both species is preferred, where possible. When the additional compound is an antibody, it will typically be administered parenterally and separately from the compound of Formula I.

In a further aspect, the invention provides a pharmaceutical composition comprising, in a pharmaceutically acceptable carrier, a compound of formula I or a pharmaceutically acceptable salt thereof and a compound of formula XI(a) or a pharmaceutically acceptable salt thereof. Preferably, the pharmaceutical composition is in a unit dose form suitable for oral administration, such as a tablet or a capsule.

EXAMPLES

The ability of the compounds of Formula I to selectively inhibit production of A β (1-42) was determined using the following assay:

γ -Secretase Modulator Cell-based Assay

Day 1

- SHSY5Y (β A4CTF) cells are grown to about 50% - 60% confluency.

- Change media on cells and add Sodium Butyrate (10mM) for ~4 hours before harvesting, counting and plating cells to 96-well plates at 35 000 cells/well in 100µL of MEM (without HEPES and phenol red) plus 10%FBS (heat treated), 50mM HEPES, 1% Glutamine.

5

- Take 200mM stock of compounds for testing and dilute in DMSO to give a ten point dose-response curve (For example: 200, 60, 20, 6, 2, 0.6, 0.2, 0.06, 0.02 and 0.006mM)

- 10
- Dilute 10µL of these diluted compounds to 182 µL with compound dilution media [MEM (without HEPES and phenol red) plus 50mM HEPES, 1% Glutamine]. This gives concentrations of 11000, 3300, 1100, 330, 110, 33, 11, 3.3, 1.1, 0.33 µM in compound dilution media/5.5% DMSO.

- 15
- Add 10µL of this dilution to the cells >2 hours after plating. Dilute 10µl DMSO into 182µl Compound dilution media and add 10µl of this mix to the cells in wells A1-H1. Dilute 10µl 2mM L-685458 in 100% DMSO into 182µl Compound dilution media and add 10µl of this mix to the cells in wells A12-H12. In the example given, final compound concentrations are therefore 1000, 300, 100, 30,

20

10, 3, 1, 0.3, 0.1 and 0.03 µM, with a final DMSO concentration of 0.5%

- Incubate overnight at 37°C, 5% CO₂.

Day 2:

25

- Make up appropriate antibody mixes as follows:

Aβ40: 2.75 ml Origen Buffer, 1µg/ml Ru-G2-10, 4µg/ml 4G8-Bio per plate

Aβ42: 2.75 ml Origen Buffer, 0.5µg/ml Ru-G2-11, 4µg/ml 4G8-Bio per plate

30

(4G8-Bio supplied by Signet Pathology Ltd, G2-10 and G2-11 supplied by Chemicon Ltd.)

- 5 • Remove 10 µl of media to fresh Costar round-bottom 96-well plate for Aβ40 measurement along with 40 µl of Origen Buffer (PBS, 2% BSA, 0.2% Tween-20). (Stock of Origen Buffer should be made fresh.)
- Remove 50µl of media to fresh 96-well plate for Aβ42 measurement.
- 10 • Add 25 µl of appropriate Origen Mix to plates and store plates at 4 °C overnight on shaker.
- To the cells and remaining media (50µl) add 5µl 10x MTS / PES (CellTiter 96® cell proliferation assay, Promega) before returning to incubator. Mix then read the
15 optical density of the plates at 492nm after ~ 4 hours.

Day 3:

- 20 • Calibrate Origen M8 Analyser (Igen Inc.) according to manufacturer's instructions.
- Make up Streptavidin Dynabead Premix as follows:
Aβ40 and Aβ42: 400 µg/ml Streptavidin Dynabeads (Dyna) in 2.75 ml Origen
25 Buffer per plate.
- Add 25µl of Bead Premix per well and incubate at room temperature for 15 minutes on shaker (if several plates, stagger start times to ensure 15 minute incubation).
- 30 • Fill all wells with 150 µl of Origen Buffer (250 µl in any empty wells)

- Read plates on Origen analyser (Takes ~10 minutes per plate)
- Analyse data using percentage of controls to calculate IC₅₀'s for Aβ₄₀, Aβ₄₂ and an LD₅₀.

5


The compounds listed in Tables 1 and 2 above all gave IC₅₀ values for Aβ(1-42) inhibition that were at least 2-fold lower than the corresponding IC₅₀ values for Aβ(1-40) inhibition, typically at least 5-fold lower, and in the preferred cases at least 10-fold lower.

10

All compounds were prepared by the methods disclosed in US 5,081,138; and the following provides a representative example:-

Scheme 1

15



Methyl 3-{3-[(2,5-dimethylphenyl)thio]-5-isopropyl-1H-indol-2-yl}-2,2-dimethylpropanoate (2)

A mixture of methyl 5-[(2,5-dimethylphenyl)thio]-2,2-dimethyl-4-oxopentanoate (1) (8.0g, 27.2mmol) [prepared from 5-bromo-2,2-dimethyl-4-oxopentanoate and 2,5-dimethylthiophenol using the method of US 5081138] and (4-isopropylphenyl)hydrazine hydrochloride (5.0g, 26.8mmol) in tert-butanol (50ml) was refluxed for 3hrs. Reaction mixture was cooled to ambient temperature and concentrated in vacuo. The residue was diluted with ethyl acetate (100ml) and sequentially washed with water (1× 100ml), hydrochloric acid (2N, 100ml) and brine (100ml). The organic extract was dried over MgSO₄, concentrated in vacuo, and purified by flash chromatography eluting with 2% ethyl acetate:hexane to afford methyl 3-{3-[(2,5-dimethylphenyl)thio]-5-isopropyl-1H-indol-2-yl}-2,2-dimethylpropanoate (2) as a off white solid (4.1g, 37%) ¹H NMR δ (ppm)(400MHz, CDCl₃): 9.11 (1 H, s), 7.32 (2 H, m), 7.10 (1 H, dd, J = 1.5, 8.5 Hz), 7.01 (1 H, d, J = 7.5 Hz), 6.76 (1 H, d, J = 7.5 Hz), 6.45 (1 H, s), 3.73 (3 H, s), 3.14 (2 H, s), 3.00-2.90 (1 H, m), 2.46 (3 H, s), 2.03 (3 H, s), 1.20-1.27 (12 H, m).

Methyl 3-{1-allyl-3-[(2,5-dimethylphenyl)thio]-5-isopropyl-1 H -indol-2-yl}-2,2-dimethylpropanoate (3)

Sodium hydride (5mg, 0.22mmol) was added in to an ice cold solution of methyl 3-{3-[(2,5-dimethylphenyl)thio]-5-isopropyl-1H-indol-2-yl}-2,2-dimethylpropanoate (2) (60mg, 0.15mmol.) in DMF (3ml) and the resultant mixture stirred for 30min at 0°C. Then a solution of allyl bromide (26.6mg, 0.22mmol) in DMF (1ml) was added slowly and stirring was continued at 0°C for 30min and then at ambient temperature for 18hrs. The reaction mixture was diluted with water (50ml) and extracted with DCM (3×50ml). The organic extracts were washed with brine (1×100ml), dried over MgSO₄ and concentrated in vacuo. The residue was purified by flash chromatography eluting with 2% ethylacetate:hexane to afford methyl 3-{1-allyl-3-[(2,5-dimethylphenyl)thio]-5-isopropyl-1H-indol-2-yl}-2,2-dimethylpropanoate (3) (53mg, 80%). ¹H NMR δ (ppm)(360MHz, CDCl₃): 7.35 (1 H, s), 7.24 (1 H, m), 7.11 (1H, m), 7.00 (1 H, d, J = 7.5 Hz), 6.75 (1 H, d, J = 7.5 Hz), 6.36 (1 H, s), 5.94-5.84 (1

H, m), 5.12 (1 H, d, J = 10.5 Hz), 4.81-4.73 (3 H, m), 3.67 (3 H, s), 3.18 (2 H, s), 3.00-2.90 (1 H, m), 2.44 (3 H, s), 2.01 (3 H, s), 1.28-1.20 (12 H, m),


3-{1-allyl-3-[(2,5-dimethylphenyl)thio]-5-isopropyl-1H-indol-2-yl}-2,2-

5 dimethylpropanoic acid (4)

A solution of lithium hydroxide (28mg, 1.2mmol) in water (1ml) was added into a solution methyl 3-{1-allyl-3-[(2,5-dimethylphenyl)thio]-5-isopropyl-1 H -indol-2-yl}-2,2-dimethylpropanoate (3) (53mg, 0.12mmol) in dioxane (2ml) and stirred at 60°C for 18hrs. The reaction mixture was diluted with hydrochloric acid (2N, 50ml) and extracted with ethyl acetate (2×50ml). The organic extract was washed with brine (1×50ml), dried over MgSO₄ and concentrated in vacuo, to afford 3-{1-allyl-3-[(2,5-dimethylphenyl)thio]-5-isopropyl-1 H -indol-2-yl}-2,2-dimethylpropanoic acid (41mg, 78%) ¹H NMR δ (ppm)(360MHz, CDCl₃): 7.36 (1 H, s), 7.25 (1H, m), 7.12 (1 H, dd, J = 1.5, 8.5 Hz), 7.00 (1 H, d, J = 7.5 Hz), 6.75 (1 H, d, J = 7.5 Hz), 6.37 (1 H, s), 5.94-5.86 (1 H, m), 5.12 (1 H, d, J = 10.5 Hz), 4.85 (2 H,m), 4.77 (1 H, d, J = 17.0 Hz), 3.22 (2 H, s), 3.01-2.91 (1 H, m), 2.44 (3 H, s), 2.00 (3 H, s), 1.23-1.27 (12 H, m).

CLAIMS:

1. A method of treating or preventing a disease associated with deposition of A β in the brain comprising administering to a patient in need thereof a therapeutically effective amount of a compound of Formula I




- wherein each R¹ is independently H, C₁₋₆alkyl or C₃₋₆cycloalkyl;
 each R² is independently H or C₁₋₆alkyl, or the two R² groups together complete a C₃₋₆cycloalkyl group;
- 10 R³ represents a hydrocarbon group of up to 10 carbon atoms optionally bearing up to 2 substituents selected from halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl and C₁₋₄alkylcarbonyloxy; or R³ represents a heteroaryl group of 5 or 6 ring atoms which is optionally benzo-fused, optionally bearing up to 2 substituents selected from C₁₋₄alkyl, halogen, CN, CF₃,
- 15 OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl and C₁₋₄alkylcarbonyloxy;
- R⁴, R⁵ and R⁶ independently represent H, halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl, C₁₋₄alkylcarbonyloxy or hydrocarbon of up to 7 carbon atoms optionally bearing a substituent selected from
- 20 halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl and C₁₋₄alkylcarbonyloxy;
- R⁷ represents a hydrocarbon group of up to 10 carbon atoms optionally bearing up to 2 substituents selected from halogen, CN, CF₃, OCF₃, C₁₋₄alkoxy, C₁₋₄alkylthio, CO₂H, C₁₋₄alkoxycarbonyl, C₁₋₄alkylcarbonyl and C₁₋₄alkylcarbonyloxy;
- 25 X represents O or S;

Y represents a bond, CH₂, CH₂CH₂, CH₂CH₂CH₂ or CH₂CH₂O; and
Z represents CO₂H or tetrazol-5-yl;
or a pharmaceutically acceptable salt thereof.

- 5 2. The method of claim 1 wherein said disease is selected from
Alzheimer's disease, cerebral amyloid angiopathy, HCHWA-D, multi-infarct
dementia, dementia puglistica and Down syndrome.
- 10 3. A method of treating, preventing or delaying the onset of dementia
associated with Alzheimer's disease, cerebral amyloid angiopathy, HCHWA-D, multi-
infarct dementia, dementia puglistica or Down syndrome comprising administering to
a patient in need thereof a therapeutically effective amount of a compound of Formula
I as defined in claim 1 or a pharmaceutically acceptable salt thereof.
- 15 4. A method for retarding, arresting or preventing the accumulation of A β
in the brain comprising administering to a subject in need thereof a therapeutically
effective amount of a compound of Formula I as defined in claim 1 or a
pharmaceutically acceptable salt thereof.
- 20 5. The method of claim 1 in which the compound of formula I is
administered to a patient suffering from mild cognitive impairment or age related
cognitive decline.
- 25 6. The method according to claim 1 wherein X is S.
7. The method according to claim 1 wherein Y is CH₂.
8. The method according to claim 1 wherein Z is CO₂H.
- 30 9. The method according to claim 1 wherein R³ in formula I is selected
from alkyl, cycloalkyl, alkyl-substituted phenyl and chloro-substituted phenyl.

10. The method according to claim 1 wherein R^7 in formula I is selected from alkyl, cycloalkyl or alkenyl of up to 6 carbon atoms, or optionally substituted phenyl.


5 11. The method according to claim 1 comprising administration of a compound according to formula II:



10 wherein R^{1a} represents C_{1-6} alkyl or C_{3-6} cycloalkyl, and R^2 - R^7 , X, Y and Z are as defined in claim 1;
or a pharmaceutically acceptable salt thereof.


12. The method according to claim 1 comprising administration of a compound according to formula III:

15



wherein n is 1 or 2 and R^1 - R^6 , X, Y and Z are as defined in claim 1;
or a pharmaceutically acceptable salt thereof.

13. A compound of formula II




5

wherein R^{1a} represents C_{1-6} alkyl or C_{3-6} cycloalkyl, and R^2 - R^7 , X, Y and Z are as defined in claim 1;
or a pharmaceutically acceptable salt thereof.

10

14. A compound of formula III:



wherein n is 1 or 2 and R^1 - R^6 , X, Y and Z are as defined in claim 1;
or a pharmaceutically acceptable salt thereof.

15

15. A pharmaceutical composition comprising, in a pharmaceutically acceptable carrier, a compound of formula II or formula III, or a pharmaceutically acceptable salt thereof.